Healthcare stocks can experience wild swings in value, often depending on the outcome of a patent application. Nowhere today was that so clear as it was with BioRestorative Therapeutics (NASDAQ:BRTX). A new patent sent its stock up nearly a third in Thursday afternoon’s trading.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The patent in question relates to BioRestorative’s ThermoStem system. The ThermoStem program is a metabolic program that targets obesity and other metabolic issues. It involves “three-dimensional scaffolds” and “brown adipocytes” that were originally created from stem cells out of adipose cells. The U.S. Patent Office offered a Notice of Allowance, which suggests that a patent is forthcoming. Reports note that this is also the second Notice of Allowance that ThermoStem has received so far.
Perhaps in even better news, as far as investors are concerned, there are only three such patents connected to this entire line of intellectual property. Thus, BioRestorative will have a lot of room to run if this goes commercial. CEO Lance Alstodt, in recent remarks, specifically pointed out that the new patent notices would afford BioRestorative more opportunities to work with other firms, providing “…collaborative and partnering opportunities.”
Alstodt isn’t the only one looking forward to the future. Insider trading at BioRestorative is clearly enthusiastic as well. Insider confidence is currently rated Positive, and insiders added $10,300 worth of shares in the last three months.
